MMedication Read More All You Need to Know About Milestone Pharmaceuticals (MIST) Rating Upgrade to Strong BuyJanuary 28, 2026 Milestone Pharmaceuticals (MIST) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1…
GGenetics Read More Opus Genetics, Inc. (IRD) Reports Q2 Loss, Lags Revenue EstimatesAugust 13, 2025 Opus Genetics, Inc. (IRD) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus…